Equities

Micropos Medical AB (publ)

MPOS:AKT

Micropos Medical AB (publ)

Actions
  • Price (SEK)1.99
  • Today's Change-0.01 / -0.50%
  • Shares traded21.70k
  • 1 Year change-9.40%
  • Beta0.4683
Data delayed at least 15 minutes, as of Sep 13 2024 17:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Micropos Medical publ AB is a Sweden-based company engaged in the development of medical devices for high precision four dimensional (4D) radiotherapy. The Company’s first product is RayPilot, an electromagnetic positioning system that enables real time information of the position of the prostate. The system works as an add-on to existing linear accelerators and enables control of a region of interest (ROI) position throughout every radiotherapy session. It consists of RayPilot receiving system, RayPilot transmitter that is placed in the ROI, and RayPilot software. The Company markets its products through sales offices in the Nordic countries, a network of distributors in Europe, the United States and Asia, and through Business to Business (B2B) partnerships with T ex Elekta and Varian & Siemens.

  • Revenue in SEK (TTM)2.68m
  • Net income in SEK-22.68m
  • Incorporated2003
  • Employees9.00
  • Location
    Micropos Medical AB (publ)Adolf Edelsvards Gata 11GOETEBORG 414 51SwedenSWE
  • Phone+46 317728100
  • Fax+46 317728091
  • Websitehttps://micropos.se/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Immunovia AB (publ)885.00k-116.12m172.45m10.00--4.40--194.86-1.30-1.300.00990.21620.0071--14.3980,454.55-93.50-41.33-133.56-44.24-6,702.03-7,553.76-13,120.79-20,879.29--2.480.3064--37.5536.48-84.09---50.93--
Bactiquant A/S13.66m-22.02m178.64m----17.20--13.08-0.6558-0.65580.40640.29060.51012.945.06---82.23-41.26-92.65-47.16-24.3412.89-161.20-71.772.73-9.480.5326---0.689--7.62------
Neola Medical AB0.00-9.47m185.20m7.00--2.51-----0.1508-0.15080.001.050.00----0.00-12.63-17.04-13.59-18.46--4,237.20---5,258.78----0.00------12.97--55.46--
Arcoma AB175.30m12.66m196.46m31.0015.523.489.831.120.95980.959813.304.282.023.969.195,654,936.0014.611.1224.242.0137.8537.667.220.75681.2518.830.04070.0030.366.4134.81--22.75--
Nanexa AB26.91m-66.68m217.11m19.00--2.50--8.07-0.6938-0.69380.24840.64110.2108-3.832.991,416,316.00-52.24-40.77-70.59-48.77118.7777.27-247.79-532.261.92--0.0174--925.42147.00-30.44--39.10--
SpectraCure AB (publ)2.36m-21.18m222.43m13.00--1.89--94.09-0.218-0.2180.02431.210.0166--24.63157,600.00-14.82-12.75-15.91-13.62442.39195.30-895.85-494.40----0.0494---3.30--19.46------
Scandinavian Medical Solutions A/S300.32m8.17m270.14m25.0032.902.3014.660.89950.19630.19637.222.811.381.8911.35--3.75--6.15--24.48--2.72--0.43075.540.3473--72.98--7.49------
Nexstim Oyj89.82m-9.45m285.46m39.00--13.48--3.18-0.1223-0.12231.190.27610.81960.22235.28214,040.30-8.62-26.77-14.02-43.9097.2492.11-10.52-38.381.24-5.510.7716---23.9422.08-201.58--19.51--
Micropos Medical AB (publ)2.68m-22.68m305.25m9.00--14.92--113.86-0.2463-0.24630.0220.13410.09940.13151.20335,122.50-84.10-64.24-111.33-82.2779.96114.76-845.91-767.573.18--0.0184--50.235.94-26.57------
INIFY Laboratories AB3.44m-51.69m306.07m23.00--4.16--88.99-1.18-1.180.07851.680.0322.990.6608---48.10---48.10--76.42---1,503.10------0.00--------------
Ortoma AB43.22m-30.78m322.32m7.00--1.95--7.46-0.8112-0.81121.244.670.22941.014.496,173,962.00-16.34-10.45-17.53-11.6486.83339.86-71.22-175.523.04--0.00-------38.87--14.14--
Acarix AB6.26m-70.95m326.01m9.00--4.81--52.10-0.1168-0.11680.00950.06970.08940.11722.47---101.38-66.93-123.43-77.1288.2779.42-1,133.87-1,483.685.21-328.980.00--7.2043.55-1.11------
Karolinska Development AB1.90m-5.65m337.08m8.00--0.2762--177.13-0.0209-0.02090.0074.560.0015--1.38237,875.00-0.45363.37-0.45783.83-----296.851,466.36----0.00210.00-12.43-8.10106.11-29.31----
Boule Diagnostics AB572.53m21.28m338.62m230.0016.240.68247.140.59150.53680.536814.4512.780.7244.193.692,511,092.002.681.673.712.4043.8643.503.702.040.92684.720.269842.244.246.1396.24-9.45-9.74--
Q linea AB4.70m-224.61m362.04m99.00--5.32--77.11-2.06-2.060.04280.58130.02770.170711.8636,968.50-132.70-59.66-356.93-66.14-56.25-378.58-4,783.96-4,046.970.6999--0.4555---65.2833.0214.64--41.94--
ContextVision AB133.06m25.82m430.74m41.0016.684.7712.453.240.34450.34451.781.211.212.334.813,433,738.0023.3929.3930.6743.2797.3998.5819.4027.153.99--0.0304--12.197.78-1.77---35.88--
Data as of Sep 13 2024. Currency figures normalised to Micropos Medical AB (publ)'s reporting currency: Swedish Krona SEK
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.